UNCY Stock — Unicycive Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.80

Market cap

$133.7M

Cash

$61.4M

Enterprise value

$72.3M

Balance sheet

Cash	$61.4M
Debt	$0.0M
Net cash	$61.4M
Enterprise value	$72.3M
Basic shares	27.9M shares
Fully diluted shares	48.4M shares
Fully diluted market cap	$232.2M
Cash per share	$2.20

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading UNCY daily closes…

Loading price history…

Pipeline assets

Oxylanthanum carbonate

Phase 3 · Active Modality: small molecule

Aliases OLC

Target phosphate

Partnerships Lee's Pharmaceutical (China/HK/Asian markets, $1M upfront); Lotus International (South Korea, $0.7M upfront)

Indications

Hyperphosphatemia in CKD patients on dialysis (Phase 3)

Status note Next-generation phosphate binder. NDA received CRL Jun 2025 and Jun 2026, both citing third-party manufacturing vendor deficiency only (no clinical efficacy/safety concerns).

UNI-494

Stage not disclosed · Active Modality: prodrug

Target SUR2B

Partnerships Sphaera Pharma (exclusive license, 2017)

Indications

Acute kidney injury (Stage not disclosed)

Status note Pro-drug of nicorandil for acute kidney injury; no trial stage disclosed in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	473,563	no change	0.10%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

UNCY — Unicycive Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders